Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Autolus Therapeutics (AUTL) has issued an announcement.
Autolus Therapeutics plc recently announced promising updates on their pivotal FELIX study of obecabtagene autoleucel, a potential treatment for relapsed/refractory adult B-cell Acute Lymphoblastic Leukemia, at the ASCO Annual Meeting. Following this, they conducted a conference call and webcast to delve into the data, engaging the investment community with insights into the study’s longer-term outcomes and additional analyses. The presented information, though not filed under SEC regulations, is a significant stride in the company’s communication with its stakeholders.
For an in-depth examination of AUTL stock, go to TipRanks’ Stock Analysis page.
